ReviewHealthcare (Basel, Switzerland)2026
Prevalence and Determinants of Never Treatment During Mass Drug Administration for Lymphatic Filariasis: A Systematic Review and Meta-Analysis.
Review in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe term "never treated" refers to individuals who self-report having never ingested tablets during any round of Mass Drug Administration (MDA) against Lymphatic Filariasis (LF). This study estimated the pooled prevalence of never-treated individuals with MDA for LF and identified factors associated with persistent non-treatment.
methodsThis systematic review and meta-analysis was registered in PROSPERO [CRD420251270067] and conducted in accordance with the PRISMA 2020 guidelines. Relevant literature was identified by searching databases, i.e., PubMed, Scopus, Cochrane Central, Embase, Web of Science, and Epistemonikos from January 2000 to December 2025, and only studies published in English were included. The AXIS tool was used to assess the study quality. A random-effects model with 95% CI was applied to estimate the pooled prevalence. Subgroup, leave-one-out sensitivity, and meta-regression analyses were conducted to explore the heterogeneity.
resultsEighteen studies including 24,940 individuals showed the pooled prevalence of never treatment during all MDA rounds at 26% (95% CI: 16% to 37%, I
conclusionsPersistently never-treated populations may represent an important programmatic barrier to LF elimination. Given the very low certainty of evidence, extreme heterogeneity, and potential publication bias, these estimates should be interpreted cautiously. Future research should ensure broader geographical representation, including both urban and rural areas, and explore structural, behavioural, and socio-cultural determinants to better target high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.